(Source: Johnson & Johnson) First Long-Acting Treatment to be Used Four Times a Year for Schizophrenia in Adults TITUSVILLE, NJ, November 19, 2014 - Janssen Research & Development, LLC (Janssen) today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration (FDA). The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule. "This innovative three-month formulation has the potential to positively affect the care of many people with...
↧
